

## Special Issue

# Cerebral Hemorrhages: From Pathophysiologic Mechanisms to Therapeutic Strategies

### Message from the Guest Editor

Cerebral hemorrhages are a group of diseases that induce brain damage and subsequent functional impairment. Brain edema, vasospasm, breakdown of the blood–brain barrier, activation of microglia/macrophages, and remodeling of the perilesional environment are major pathological substrates in hemorrhagic stroke. A wide variety of conditions, risk factors, and disorders (such as hypertension, aneurysm, tumor, trauma, arteriovenous malformation, etc.) lead to cerebral hemorrhages, although the underlying pathophysiologic mechanisms remain unclear and effective treatments are limited.

This Special Issue focuses on the pathophysiologic mechanisms of primary and secondary brain injury, the mechanism of aging, mechanisms of impaired blood–cerebrospinal fluid barriers, and perilesional environment remodeling leading to immune cells infiltration and microbleeds. This Special Issue also welcomes articles that provide an overview of the role of white matter injury, phagocytosis, hemolysis, and immune system molecular mechanisms in the pathogenesis of cerebral hemorrhage diseases and corresponding treatment approaches.

---

### Guest Editor

Dr. Yingfeng Wan

Department of Neurosurgery, Medical School, University of Michigan, Ann Arbor, MI 48109, USA

---

### Deadline for manuscript submissions

closed (31 January 2025)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/176309](https://mdpi.com/si/176309)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).